Navigation Links
Leading ALS Researcher Joins the Kansas City University of Medicine and Biosciences
Date:8/14/2014

KANSAS CITY, Mo., Aug.14, 2014 /PRNewswire-USNewswire/ -- The Kansas City University of Medicine and Biosciences (KCUMB) announces the appointment of Jingsong Zhou, Ph.D., as a research investigator and professor of physiology in the College of Osteopathic Medicine. Dr. Zhou is an internationally renowned researcher and an important addition to KCUMB's growing research efforts. KCUMB recently made a strategic shift to focus on advancing the scientific exploration of biomedical and translational research.

Dr. Zhou is an international leader in neuromuscular disease research, including amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease. Dr. Zhou is recognized for her significant contributions to advancing the scientific understanding in those, and other neurologic conditions such as Alzheimer's Disease. She has been on the cutting edge of biotechnology of Calcium imaging in living cells and is credited for the development of molecular biosensors of the mitochondria (the power plant for all cells) which has broad applications in a number of diseases.

Dr. Zhou brings the unique perspective of a biophysicist to understanding neuromuscular diseases, and is a well-funded investigator by the National Institutes of Health. She was most recently an associate professor in the Department of Molecular Physiology and Biophysics at Rush University School of Medicine in Chicago. Prior to her tenure at Rush University she was a research associate for the Department of Pharmacology at Vanderbilt University in Nashville, Tenn., and served as a teaching and research assistant for the Department of Physiology at Hunan Medical University in China.

"KCUMB is honored to welcome an internationally recognized research expert, Dr. Zhou, to our team," said Jeffrey Joyce, Ph.D., vice president for research. "Dr. Zhou brings years of expertise in molecular biophysics and physiology research, a collaborative entrepreneurial outlook to research and we look forward to her leadership and impact here at KCUMB and within the region's research community."

As research investigator, Dr. Zhou's responsibilities will include leading key biomedical and translational research initiatives, particularly in the neuroscience arena, collaborating with researchers at other local organizations, including the Kansas City Area Life Sciences Institute and its key stakeholders, and providing student research opportunities.

"We are delighted Dr. Zhou is joining KCUMB," said Dr. Richard Barohn, vice chancellor for research at the University of Kansas Medical Center. "In doing so, she will become a member of Frontiers: The Heartland for Clinical and Translational Research and will work with a number of scientists exploring the pathogenesis of severe neurodegenerative disorders such as ALS and Alzheimer's disease.  With Dr. Zhou's hire, we have developed a critical mass of cutting edge researchers who are making important discoveries in these diseases."

With this hire KCUMB is committing significant resources to expand its laboratory facilities on campus, establish a scientific core in the neurosciences and invest in additional scientific research equipment to enhance these new research efforts.

"Dr. Zhou and her staff will be key components of enhanced neuroscience research not only on the KCUMB campus, but her unique research focus will be a resource to the greater Kansas City scientific community," said Marc B. Hahn, D.O., president and chief executive officer for KCUMB. "She will truly add to the scholarly foundation of our University and be a mentor for our students."

Dr. Zhou is the recipient of the Outstanding Research Award from the Sigma Xi Scientific Research Society, the Medical Staff Award from Rush University, and the American Heart Association Fellowship Award. Dr. Zhou has been a member of the Biophysical Society since 1993, and a member of the American Physiology Society since 2013.

She earned her doctorate in physiology and biophysics from Rush University in July 1997.

About KCUMB
The Kansas City University of Medicine and Biosciences, founded in 1916, is a fully accredited, private university, with a College of Biosciences and a College of Osteopathic Medicine. The College of Osteopathic Medicine is the oldest medical school in Kansas City, Mo., and the largest in the state. It is the second-largest provider of physicians within the states of Missouri and Kansas, with 73 percent practicing in a primary care specialty throughout the Midwest region.

Contact: Brian Van Note
Account Executive
(913) 660-9656
(816) 810-7785 (cell)
bvannote@morningstarcomm.com

Lisa Cambridge
Director of Public Relations
(816) 654-7038
(913) 602-8652 (cell)
lcambridge@kcumb.edu


'/>"/>
SOURCE Kansas City University of Medicine and Biosciences (KCUMB)
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Clinovo White Papers Published in Summer 2014 Editions of Leading Medical Device & Pharmaceutical Publications
2. Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting
3. Leading Cancer Immunotherapy Biotech Startup Announces New Investments, Leadership Appointments
4. Menon Biosensors Demonstrates Industry Leading Sensitivity Levels for Detection of Tuberculosis and Clostridium difficile
5. WaferGen Bio-systems Acquires a Leading Next-Generation Sequencing (NGS) Library Preparation Business and Announces Changes to its Board of Directors
6. New 2 Hour Educational Learning Labs at MD&M West Will Feature Baxter Bioscience, BMW, Dell, GE Healthcare, Mattel, Northrup Grumman, Starbucks and Other Leading Groups in Design, Manufacturing, Engineering and Automation
7. Arsenal Capital Partners Acquires Leading Model-Based Drug Development Company Certara
8. Gregory Frank Named President of Two Leading Immunology Biotech Companies; Pure Protein and Pure MHC
9. Leading Cancer Research Centers Team Up To Launch Biotech Startup Focused On Cancer Immunotherapy
10. The Future is Bright for Formedix, Leading Clinical Trial Software Provider
11. NSF International Acquires Brazil’s Bioensaios Analysis and Environmental Consultancy Ltd., a Leading Analytical Laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
(Date:2/10/2016)... ... 10, 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics will feature ... in San Francisco’s Moscone Center from February 16-18, 2016, and at the healthcare-focused ... latest InGaAs PIN diode standard packages feature a TO-46 metal can with active areas ...
(Date:2/10/2016)... ... February 10, 2016 , ... Curoverse announced today ... Azure, Arvados provides capabilities for managing and processing genomic and health data at ... major institutions collecting and analyzing genomic data,” said Adam Berrey chief executive officer ...
(Date:2/10/2016)... ... February 09, 2016 , ... ... current winner of the Highest Overall Customer Rating Award from Circuits Assembly ... its business units across the USA, Canada, Mexico and China. , The EMS ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 ... of the "Emotion Detection and Recognition ... and Others), Software Tools (Facial Expression, Voice ... Users,and Regions - Global forecast to 2020" ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has announced the ...
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)... NEW YORK , Feb. 1, 2016  Today, ... Heart Association (AHA) announced plans to develop a first ... cognitive computing power of IBM Watson. In the first ... disease, AHA, IBM (NYSE: IBM ), and Welltok ... metrics and health assessments with cognitive analytics, delivered on ...
Breaking Biology News(10 mins):